10/24/2013 | 03:14pm US/EasternRecommend: 0 Zeltia recovers sales and margins during the third quarter of the year
• Gross sales of Yondelis® up to 30 September 2013 rose by
17.5% with respect to the same period in 2012.
• EBITDA for the oncology business grew 12% during the first nine months of the year compared to the same period last year, contributing 25.9 million Euros to the total Group EBITDA.
• Up to 30 September, the Zeltia Group registered an attributable net profit of 14 million Euros (+64.9% vs the same period last year) as a result of the concentration in the oncology business.
• The Group reduced its total debt by 13% with respect to the beginning of the year.
Madrid, 24 October 2013: During the first nine months of the year, gross sales of Yondelis® increased by 17.5% with respect to the same period last year. This increase is due, to a large extent, to the restoration of the supply of Caelyx® in May. Caelyx® is the drug administered in combination with Yondelis® for the treatment of relapsed ovarian cancer. Net sales of Yondelis® up to September 2013 were 53.2 million Euros which is a 7.2% increase year-on-year even after factoring in the price discounts applied by various European countries. Nevertheless, this increase represents 12% if we consider commercial sales only. That is, sales without taking into account the effect of the sale of raw material to our partners which took place in 2012.
...